Esophagus Cancer Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0032126 (Esophagus Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03342937KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric CancerTreatment